Breast Cancer Now media statements
Our response to new analysis from Cancer Research UK revealing more than 300,000 cancer patients face delays over the next five years
Responding to new analysis from Cancer Research UK revealing more than 300,000 cancer patients will face treatment delays over the next five...
We respond to the National Audit of Metastatic Breast Cancer State of the Nation Report 2024
Melanie Sturtevant, associate director of policy, evidence and influencing, at Breast Cancer Now, said:
We respond to Ali Bastian's breast cancer diagnosis
Louise Grimsdell, senior clinical nurse specialist at Breast Cancer Now, said:
We respond to Elle Macpherson sharing her breast cancer diagnosis 7 years ago
Jane Murphy, clinical nurse specialist at Breast Cancer Now, said:
Breast Cancer Now responds to latest vacancy rates among screening mammographers
Responding to the latest vacancy rates among screening mammographers, Rachael Franklin, interim chief executive at Breast Cancer Now, said:
We respond to Royal College of Radiologists' 2023 Clinical Radiology and Oncology Census Reports
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
We respond to new data presented at ASCO 2024 congress, which found that women taking Enhertu survived without their breast cancer growing for an average of 13 months
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
We respond to research that has shown breast cancer rates increasing amongst younger people
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
We respond to research about a new blood test that predicts recurrence of breast cancer
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
We respond to NICE recommendation of tumour profiling tests to guide adjuvant chemotherapy decisions for certain patients
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said: